Drug record
What four public record sets show for adalimumab. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | Brand prices only, see table | Details |
| Medicare Part D, 2024 | $5.88 billion | Details |
| FDA recall records | 1 | Details |
Whether the FDA lists this drug as in short supply.
6 products being discontinued. A maker has told the FDA it will stop making these. That is one maker leaving, not a shortage of the drug:
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| HADLIMA 40 MG/0.8 ML SYRINGE | Brand | $617.14 per mL | — | Oct 21, 2026 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | Brand | $632.97 per mL | — | Oct 21, 2026 |
| HADLIMA(CF) 40 MG/0.4 ML SYRINGE | Brand | $1,258.09 per mL | — | Oct 21, 2026 |
| HADLIMA(CF) PUSHTOUCH 40 MG/0.4 ML | Brand | $1,259.45 per mL | — | Oct 21, 2026 |
| HUMIRA 40 MG/0.8 ML SYRINGE | Brand | $3,368.96 per each | $101,068.72 | Oct 21, 2026 |
| HUMIRA PEN 40 MG/0.8 ML | Brand | $3,366.95 per each | $101,008.50 | Oct 21, 2026 |
| HUMIRA(CF) 20 MG/0.2 ML SYRINGE | Brand | $3,366.12 per each | $100,983.69 | May 20, 2026 |
| HUMIRA(CF) 40 MG/0.4 ML SYRINGE | Brand | $3,368.44 per each | $101,053.10 | Oct 21, 2026 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | Brand | $3,367.85 per each | $101,035.51 | Oct 21, 2026 |
| HUMIRA(CF) PEN 80 MG/0.8 ML | Brand | $6,735.20 per each | $202,055.86 | Oct 21, 2026 |
| YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR | Brand | $896.51 per each | $26,895.40 | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $5.88 billion for the 41 products below. That is up 42% from $4.15 billion in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | $4.33 billion | 63,768 | $8,828.62 | $67,881.99 | $2.17 billion |
| Humira Pen Adalimumab | $697.4 million | 11,719 | $8,188.68 | $59,510.64 | $1.22 billion |
| Humira(Cf) Adalimumab | $400.9 million | 6,661 | $8,599.32 | $60,186.23 | $305.6 million |
| Humira Adalimumab | $208.9 million | 3,912 | $8,185.62 | $53,401.11 | $383.6 million |
| Humira(Cf) Pen Crohn'S-Uc-Hs Adalimumab | $59.2 million | 2,792 | $20,489.93 | $21,209.13 | $46.3 million |
| Cyltezo(Cf) Pen Adalimumab-Adbm | $52.7 million | 1,146 | $8,018.50 | $45,955.95 | — |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | $36.9 million | 4,088 | $1,632.45 | $9,020.02 | — |
| Yuflyma(Cf) Autoinject (2 Pck) Adalimumab-Aaty | $22.4 million | 451 | $8,550.13 | $49,556.62 | — |
| Humira(Cf) Pen Psor-Uv-Adol Hs Adalimumab | $20.7 million | 1,497 | $13,580.52 | $13,852.68 | $25.6 million |
| Hyrimoz(Cf) Pen Adalimumab-Adaz | $7.9 million | 468 | $6,010.85 | $16,966.51 | — |
| Amjevita(Cf) Adalimumab-Atto | $6.3 million | 710 | $1,633.68 | $8,881.70 | — |
| Yuflyma(Cf) Autoinjector Adalimumab-Aaty | $5.8 million | 172 | $7,852.08 | $33,736.57 | — |
| Cyltezo(Cf) Adalimumab-Adbm | $5.5 million | 147 | $7,423.61 | $37,168.56 | — |
| Hadlima(Cf) Pushtouch Adalimumab-Bwwd | $4.9 million | 959 | $1,129.49 | $5,125.68 | — |
| Adalimumab-Adaz(Cf) Pen Adalimumab-Adaz | $4.7 million | 740 | $1,753.46 | $6,331.40 | — |
| Idacio(Cf) Pen (2 Pack) Adalimumab-Aacf | $3.0 million | 90 | $8,201.79 | $32,898.31 | — |
| Yuflyma(Cf) (2 Pack) Adalimumab-Aaty | $2.7 million | 56 | $8,888.77 | $49,046.96 | — |
| Hyrimoz(Cf) Adalimumab-Adaz | $965,139 | 55 | $6,434.26 | $17,547.99 | — |
| Cyltezo(Cf) Pen Crohn'S-Uc-Hs Adalimumab-Adbm | $955,713 | 44 | $21,238.07 | $21,720.76 | — |
| Adalimumab-Aacf(Cf) Pen (2 Pk) Adalimumab-Aacf | $818,540 | 166 | $1,054.82 | $4,930.96 | — |
| Hadlima(Cf) Adalimumab-Bwwd | $751,584 | 153 | $1,167.06 | $4,912.32 | — |
| Hadlima Pushtouch Adalimumab-Bwwd | $735,326 | 135 | $1,012.85 | $5,446.86 | — |
| Adalimumab-Adbm(Cf)pen Adalimumab-Adbm | $658,270 | 119 | $1,571.05 | $5,531.68 | — |
| Yusimry(Cf) Pen Adalimumab-Aqvh | $650,429 | 98 | $1,184.75 | $6,637.03 | — |
| Cyltezo(Cf) Pen Psoriasis-Uv Adalimumab-Adbm | $546,920 | 30 | $14,023.58 | $18,230.66 | — |
Showing the 25 largest of 41 products.
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year.
Recalls reported to the FDA that name this drug.
The FDA has 1 recall record that name adalimumab in the product description (1 Class II). 1 are still marked ongoing.
HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.
Reason: Lack of Assurance of Sterility.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for adalimumab. This page is public-record information, not medical advice.